or Try an Advanced Search...

    Technical Analysis for BCAB - BioAtla, Inc.

    Grade Last Price % Change Price Change
    F 1.43 -3.38% -0.05
    BCAB closed down 1.33 percent on Wednesday, November 20, 2024, on 48 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical BCAB trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness -3.38%
    Wide Bands Range Expansion -3.38%
    Down 3 Days in a Row Weakness -3.38%
    Down 4 Days in a Row Weakness -3.38%
    Down 5 Days in a Row Weakness -3.38%
    Lower Bollinger Band Touch Weakness -3.38%
    Oversold Stochastic Weakness -3.38%
    NR7 Range Contraction -4.67%
    NR7-2 Range Contraction -4.67%
    Narrow Range Bar Range Contraction -4.67%
    Older End-of-Day Signals for BCAB ...

       Recent Intraday Alerts

    Alert Time
    Down 10% about 2 hours ago
    Fell Below Lower Bollinger Band about 3 hours ago
    2x Volume Pace about 3 hours ago
    Down 5% about 3 hours ago
    60 Minute Opening Range Breakdown about 3 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    BCAB Chart by TradingView
    Basic chart:

    Profile

    BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Health Care Tumor Cancer Immunotherapy Monoclonal Antibodies Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Targeted Therapy Hepatocellular Carcinoma Bladder Cancer NSCLC Non Small Cell Lung Carcinoma Renal Cell Carcinoma Cervical Cancer Gastric Cancer

    Is BCAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades
    Nov 9 BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
    Nov 8 BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
    Nov 8 3 Promising US Penny Stocks With At Least $90M Market Cap
    Nov 7 BioAtla GAAP EPS of -$0.22 beats by $0.15, revenue of $11M
    Nov 7 BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
    Oct 31 BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
    Oct 30 BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake
    Oct 20 BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025
    Oct 9 BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
    See more BCAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.02
    52 Week Low 1.14
    Average Volume 1,314,372
    200-Day Moving Average 2.13
    50-Day Moving Average 1.90
    20-Day Moving Average 1.94
    10-Day Moving Average 1.86
    Average True Range 0.21
    RSI (14) 35.06
    ADX 29.63
    +DI 17.24
    -DI 24.27
    Chandelier Exit (Long, 3 ATRs) 1.91
    Chandelier Exit (Short, 3 ATRs) 2.05
    Upper Bollinger Bands 2.44
    Lower Bollinger Band 1.44
    Percent B (%b) 0.04
    BandWidth 51.28
    MACD Line -0.10
    MACD Signal Line -0.02
    MACD Histogram -0.0805
    Fundamentals Value
    Market Cap 70.94 Million
    Num Shares 47.9 Million
    EPS -2.65
    Price-to-Earnings (P/E) Ratio -0.56
    Price-to-Sales 989.22
    Price-to-Book 1.47
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.64
    Resistance 3 (R3) 1.64 1.59 1.61
    Resistance 2 (R2) 1.59 1.55 1.59 1.60
    Resistance 1 (R1) 1.53 1.52 1.51 1.53 1.59
    Pivot Point 1.48 1.48 1.47 1.48 1.48
    Support 1 (S1) 1.43 1.44 1.40 1.43 1.37
    Support 2 (S2) 1.38 1.42 1.38 1.36
    Support 3 (S3) 1.32 1.38 1.35
    Support 4 (S4) 1.32